Maternal-Fetal Medicine, Intermountain Healthcare, University of Utah, 5121 South Cottonwood Street, Suite 100, Murray, UT 84107, USA.
Maternal-Fetal Medicine, Intermountain Healthcare, University of Utah, 30 North 1900 East, 2A200, Salt Lake City, UT 84132, USA. Electronic address: https://twitter.com/Nateyblue.
Obstet Gynecol Clin North Am. 2021 Jun;48(2):297-310. doi: 10.1016/j.ogc.2021.03.001.
Fetal growth restriction (FGR) is a common clinical manifestation of placental insufficiency. As such, FGR is a risk factor for stillbirth. This association has been demonstrated in numerous studies but is prone to overestimation because of the possibility of prolonged in utero retention before the recognition of the fetal death. Stillbirth risk reduction by optimizing maternal medical conditions and exposures and appropriate antenatal testing and delivery timing are essential to pregnancies affected by FGR. It is important to evaluate stillbirths with FGR with fetal autopsy, placental pathology, genetic testing, and assessment of antiphospholipid antibodies and fetal-maternal hemorrhage.
胎儿生长受限（FGR）是胎盘功能不全的常见临床表现。因此，FGR 是死胎的一个危险因素。这种关联在许多研究中都得到了证实，但由于在确认胎儿死亡之前可能存在宫内滞留时间延长，因此存在高估的可能性。通过优化母体的医疗条件和暴露情况以及适当的产前检查和分娩时机，可以降低 FGR 妊娠的死产风险。对伴有 FGR 的死产进行胎儿尸检、胎盘病理、基因检测以及抗磷脂抗体和胎儿-母体出血评估非常重要。
